JVJacqueline Vuong

Jacqueline Vuong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jacqueline Vuong has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Geographic variation in public interest about amyloidosis in the United States and English speaking countries

    by Jacqueline Vuong, Avinainder Singh, Rodney H. Falk, Raina Merchant, Sharmila Dorbala

    (2020). Geographic variation in public interest about amyloidosis in the United States and English speaking countries. Amyloid. Ahead of Print.


  • Mortality From Heart Failure and Dementia in the United States: CDC WONDER 1999–2016

    by Jacqueline T Vuong, Sophia A Jacob, Kevin M Alexander, Avinainder Singh, Ronglih Liao, Akshay S Desai, Sharmila Dorbala


  • Open Access

    Intranasal delivery of VEGF enhances compensatory lung growth in mice

    by Duy T Dao, Jacqueline T Vuong, Lorenzo Anez-Bustillos, Amy Pan, Paul D Mitchell, Gillian L Fell, Meredith A Baker, Diane R Bielenberg, Mark Puder

    Vascular endothelial growth factor (VEGF) has previously been demonstrated to accelerate compensatory lung growth (CLG) in mice and may be a useful therapy for pulmonary hypoplasia. Systemic administration of VEGF can result in side effects such as hypotension and edema. The aim of this study was to explore nasal delivery as a route for intrapulmonary VEGF administration. Eight-week-old C57BL/6 male mice underwent left pneumonectomy, followed by daily nasal instillation of VEGF at 0.5 mg/kg or isovolumetric saline. Lung volume measurement, morphometric analysis, and protein expression studies were performed on lung tissues harvested on postoperative day (POD) 4. To understand the mechanism by which VEGF accelerates lung growth, proliferation of human bronchial epithelial cells (HBEC) was assessed in a co-culture model with lung microvascular endothelial cells (HMVEC-L) treated with and without VEGF (10 ng/mL). The assay was then repeated with a heparin-binding EGF-like growth factor (HB-EGF) neutralizing antibody ranging from 0.5–50 μg/mL. Compared to control mice, the VEGF-treated group displayed significantly higher lung volume (P = 0.001) and alveolar count (P = 0.005) on POD 4. VEGF treatment resulted in increased pulmonary expression of HB-EGF (P = 0.02). VEGF-treated HMVEC-L increased HBEC proliferation (P = 0.002) while the addition of an HB-EGF neutralizing antibody at 5 and 50 μg/mL abolished this effect (P = 0.01 and 0.002, respectively). These findings demonstrate that nasal delivery of VEGF enhanced CLG. These effects could be mediated by a paracrine mechanism through upregulation of HB-EGF, an epithelial cell mitogen.


  • Top Cited Papers

    Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice

    by José J. Fuster, Susan MacLauchlan, María A. Zuriaga, Maya N. Polackal, Allison C. Ostriker, Raja Chakraborty, Chia-Ling Wu, Soichi Sano, Sujatha Muralidharan, Cristina Rius, et al.

    Faulty blood cells and heart disease: Recent studies have shown that elderly people's blood cells often harbor mutations in genes encoding certain epigenetic regulators. These mutations can lead to clonal expansion of the mutant blood cells, which increases the risk of blood cancers and cardiovascular disease. Fuster et al. generated a mouse model to investigate how one of these genes, Tet2 , affects atherosclerosis development (see the Perspective by Zhu et al. ). They found that the disease progressed more rapidly in mice transplanted with Tet2 -deficient bone marrow cells. This was due to increased secretion of interleukin-1β by Tet2 -deficient macrophages in a process that depended on the action of inflammasomes. Science , this issue p. 842 ; see also p. 798